---
title: "Reviva Pharmaceuticals Holdings, Inc. (RVPH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RVPH.US.md"
symbol: "RVPH.US"
name: "Reviva Pharmaceuticals Holdings, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:31:04.866Z"
locales:
  - [en](https://longbridge.com/en/quote/RVPH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RVPH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RVPH.US.md)
---

# Reviva Pharmaceuticals Holdings, Inc. (RVPH.US)

## Company Overview

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.revivapharma.com](https://www.revivapharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.32 | 81 | - | - | - |
| PB | 0.30 | 12 | 9.40 | 6.59 | 1.18 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.41 |
| Highest Target | 140.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RVPH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RVPH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RVPH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RVPH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**